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Abstract
There is some evidence that breast cancer surgery during the luteal phase in pre-menopausal
women is associated with a better clinical outcome, however the evidence for this is still equivocal.
In this paper, after summarizing the normal physiology of the menstrual cycle, we examine how
such an association may occur and provide a comprehensive review of the literature in the area.
Background
Breast cancer is a significant disease affecting over 41,000
women each year in the UK [1]. One in three of these
patients are younger than 55 when the diagnosis of breast
cancer is made, and almost all will undergo wide local
excision or mastectomy.
Amongst the significant sub-group of pre-menopausal
patients the tumour is likely to be subject to cyclical fluc-
tuations in the hormonal milieu. Any impact on survival
from the coordination of surgery with the phase of the
menstrual cycle should therefore be explored and changes
to clinical practice could be implemented as indicated.
There is some evidence that breast surgery during the
luteal phase in pre-menopausal women is associated with
better outcomes, however the evidence for this is not con-
sistent (see table 1)
Although there are data suggesting that hormonal factors
influence tumour characteristics and behaviour, however
there is no definitive evidence that surgery should be
scheduled to avoid the follicular phase. A number of stud-
ies have investigated the biochemical and clinical
response of tumours resected during the various phases of
the menstrual cycle [2-4]. In addition, the hormonal sta-
tus of a patient may have an impact on intra-operative fac-
tors such as bleeding [5], and may be also significant for
the timing of core biopsies [6].
In this paper, after summarizing the normal physiology of
the menstrual cycle, we examine how such an association
may occur and provide a comprehensive review of the lit-
erature in the area.
Normal physiology
The menstrual cycle is a rhythmic preparation for extru-
sion of an ovum and subsequent pregnancy if the ovum is
fertilized. The events are under the influence of the
hypothalamic gonadotrophins follicle stimulating hor-
mone (FSH) and luteinising hormone (LH) that regulate
the release of sex steroid hormones estrogen and proges-
terone from the ovarian interstitium. These in turn prime
the ovarian follicles and induce ovulation. Assuming that
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Day 0 is the first day of menstrual flow of the last men-
strual period, all hormones are low for the first 4–5 days.
This is the early period of follicular development. Estro-
gens gradually rise for the next 3–4 days followed by a
rapid peak by 12th day which is the day before the LH and
FSH peak. Ovulation then occurs 24–36 h after the LH
peak by about the 14th day. The second peak of estrogen
occurs about a week after ovulation and is opposed by a
progesterone peak. Furthermore, progesterone shows a
small increase in concentration corresponding to the LH
surge. Hence estrogen remains unopposed during the fol-
licular phase, up to Day 12, while during the rest of the
cycle progesterone opposes the action of estrogen.
The hypotheses
In 1989 Hrushesky et al. were the first to propose that pre-
menopausal patients with breast cancer who underwent
surgery during the luteal phase of the menstrual cycle had
higher disease-free and overall survival rates than did
patients operated on during other phases of the cycle [7].
It is indeed an intriguing aspect of the treatment of breast
cancer that the timing of breast surgery, in relation to
menstrual cycle phase and hence hormonal status, might
influence the natural history and prognosis of the disease.
The biological-endocrinological basis for this is two-fold:
Firstly, in the follicular phase, estrogens reduce immune
activity, phagocytic activity and circulating levels of IL-2
therefore potentially increasing metastatic potential of
breast cancer cells [8]. At the same time they stimulate the
activity of insulin-like growth factor (IGF), which has
been proven in several studies to have an important
mitogenic effect on breast cells [9-11]. Furthermore, ang-
iogenesis, a process vital for the progression of many
tumours and hence for their ability to metastasise, is
favoured by high circulating levels of estrogens since they
promote expression of vascular endothelial growth factor
(VEGF) [12,13].
Secondly, in the luteal phase the increase in circulating
levels of endogenous progesterone may modulate the pro-
liferation of normal and neoplastic breast tissue and
increase intercellular cohesion thereby reducing meta-
static potential [14,15]. Progesterone also acts to regulate
the IGF1 (pro-mitotic effect)/TGFb (anti-mitotic effect)
balance. Moreover progestogens act to reduce the number
Table 1: Summary of key studies
Year Author Study Design Outcome measure Outcome difference P value
2003 Takeda [31] Retrospective
n = 36
Disease-free survival Nil n/a
2002 Fentiman [29] Prospective
n = 249
10 year survival 84% luteal
54% follicular
-
2001 Pujol [30] Prospective
n = 360
Disease-free survival nil n/a
1999 Nomura [32] Retrospective
n = 721
Disease-free survival nil n/a
1998 Mangia [33] Retrospective
N = 248
Disease-free survival Nil n/a
1998 Harlap [34] N = 614 10-year survival nil n/a
1997 Goldhirsch [35] RCT
n = 300
Disease-free survival (ER-ve) 59% luteal
42% follicular
P = 0.008
1997 Vanek [36] Retrospective Overall Survival Nil n/a
1997 Mondini [37] N = 165 Overall Survival Nil n/a
1995 Jager [38] Retrospective
n = ?
Disease-free survival nil n/a
1995 Holli [39] N = 267 Overall Survival nil n/a
1994 Kroman [40] N = 1635 Overall Survival nil n/a
1994 Corder [41] N = 157 Overall Survival nil n/a
1994 Saad [42] Retrospective
N = 96
Overall Survival 79% lut
40% foll,
P < 0.001
1992 Gnant [43] Retrospective
n = 385
Overall Survival nil n/a
1991 Badwe [27] Retrospective
n = 75
Overall survival 54% follicular
84% luteal
P < 0.001
1991 Senie [44] Prospective
n = 283
Disease-free survival 71% luteal
57% follicular
P = 0.02
1989 Hrushesky [7] Retrospective
N = 44
Overall Survival 95% luteal
79% follicular
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of estrogen receptors expressed on breast cells hence lim-
iting estrogenic stimulation and as a result promoting
breast cell apoptosis [16].
Excision of tumours in the presence of unopposed oestro-
gen has been reported to be associated with improved sur-
vival. This was initially suggested by the better outcomes
of peri- and post-menopausal patients. Thin patients, with
less peripheral aromatase, have lower oestrogen com-
pared to obese patients [17]. An improved outcome in
these groups has been demonstrated in meta-analysis in
both pre and post menopausal patients [18] but this does
not prove causation. Furthermore, many patients in these
groups may have compounding factors causing the varia-
tion in survival.
It has been demonstrated that there is a reduced breast
tumour growth during the pre or peri-ovulatory phases,
but the tumour then increases in size during the post-ovu-
latory phase, before shrinking back towards the original
dimension. In animal studies, mice with faster cycles have
slower tumour growth rates. This correlation has even
been demonstrated in animal models of non-hormone
dependant tumours (sarcoma) [19].
Increased adrenergic immunosuppression
During the menstrual cycle, fluctuation in hormone levels
produce a modulation of adrenergic mechanisms and
through this NK cells responsible for metastasis control
become suppressed secondary to increased adrenergic
tone during the follicular phase [20]. Animal studies have
also confirmed this correlation between NK metastasis
suppression and adrenergic modulation during oestrous,
which can be increased with an exogenous beta agonist
[21].
Vascular endothelial growth factor
In the female reproductive system angiogenesis occurs as
a normal process and is essential for normal tissue devel-
opment. In the ovary new blood vessel formation facili-
tates oxygen and nutrient delivery and allows the transfer
of hormones to targeted cells, ovarian follicles and the
corpus luteum have been shown to produce several ang-
iogenic factors, of which vascular endothelial growth fac-
tor (VEGF) is thought to be paramount. VEGF levels
fluctutate within the breast with greater concentrations
occurring during the luteal phase [22], interestingly there
is no evidence for a corresponding fluctuation in serum
levels [23]. This modulation of proangiogenic cytokines
in the breast may contribute to the reduced potential for
metastasis in tumours resected during the luteal phase
[22-24].
Tumour epidermal growth factor
A prospective study of premenopaual women measured
the concentrations of oestrogen, porlaction, progesterone,
tumour epidermal growth factor and tumour epidermal
growth factor receptor. While levels of tumour epidermal
growth factor remained constant EGFR levels peaked dur-
ing the follicular phase [25]. This cyclical up-regulation
may contribute to the worse prognosis potentially associ-
ated with surgery during this phase. Other studies have
demonstrated that the EGF receptor is localised in the epi-
thelial cells during the luteal phase [26].
Other factors
Surgery for benign disease such as mammaplasty, associ-
ated with reduced intraoperative bleeding and avoidance
of a post-operative drain if carried out during the periovu-
latory phase [5]. Increased tumour vascular invasion and
Her-2 expression during the follicular phase ans regula-
tion of matrix metallo-proteinases (MMP 2 & 9) and MMP
tissue inhibitors (TIMP-1 & 2) are also potential factors
[27-29].
Review of the literature
In the following paragraphs we will attempt to review the
literature, so far published on this intriguing hypothesis,
and therefore identify the clinical implications that such a
hypothesis has in relation to the treatment of breast can-
cer. There has been no comprehensive systematic review
of literature since 2001, despite recent published evidence
in this area.
The relationship between the menstrual cycle and surgical
outcome was first described by Hrushesky in 1989 [7].
Based on a retrospective study of 44 patients, it was postu-
lated that surgery carried out on premenopausal patients
during the luteal phase confers higher disease free survival
(DFS) compared to patients who underwent surgery at
other times.
In 1991 Badwe et al [27], suggested that unopposed oes-
trogen may be associated with increased mortality, with a
10 year survival rate of 54% in the patients whose surgery
took place during days 2–13, compared to 84% in those
undergoing surgery between days 0–2 and 13–32.
A large meta-analysis using a fixed effect model of 37 pub-
lished studies (n = 10476) was conducted in 2000 [28]
and demonstrated a 15% (+/- 4%) increase in survival
when tumours were resected during the luteal phase (p =
0.003), however three further studies [29-31] have been
carried out since then, adding significantly to the body of
evidence in this field.
In 2002, a retrospective analysis of prospectively collected
data and serum samples from 249 pre-menopausalInternational Seminars in Surgical Oncology 2006, 3:37 http://www.issoonline.com/content/3/1/37
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patients undergoing resection of breast tumours showed
that in both node positive and node negative tumours, the
10 year survival is improved by carrying out surgery dur-
ing the luteal phase which was defined by both last men-
strual period (LMP) and serum progesterone [29]. The 10-
year survival for node positive cases undergoing follicular
phase surgery was 33% compared with 78% in those hav-
ing surgery at other times of the menstrual cycle.
Conversely, a prospective study of 360 pre-menopausal
patients, published in 2001, using hormonal assays to
time the menstrual phase demonstrated no prognostic
influence of coordinating surgery with the luteal phase
[30]. Furthermore, a more recent small study of 36
patients showed that the recurrence rate and relapse-free
survival were not significantly different with the men-
strual timing of surgery [31]. However, patients with early
breast cancer undergoing surgery during the follicular
phase and those with advanced breast cancer resected dur-
ing the luteal phase appeared to show better prognosis
than corresponding controls operated during the other
phases.
Table 1 summarises the key studies in this field including
several studies [32-44] already used in the 2000 meta-
analysis [28].
Discussion
There is clearly a controversy surrounding the most appro-
priate timing of breast cancer surgery and there is incon-
sistent evidence supporting the notion that resection
during the luteal phase improves outcome. Twenty-two
out of the 40 studies published were in favour of luteal
phase surgery compared with 9 studies in favour of follic-
ular phase surgery [28]. The remainder of studies (n = 9)
showing no significant difference between the two phases.
However breast cancer amongst pre-menopausal women
is such a critical topic that even modest advantages in out-
come should be exploited.
Many of the initial studies in this field were undertaken
retrospectively and often relied on inaccurate assessment
of the hormonal status of the patient. Using the LMP to
define the cycle phase is thought to be inaccurate since
factors such as peri-operative stress and the impact of a
recent diagnosis of breast cancer may result in disruption
of the normal menstrual cycle or even an anovulatory
cycle. However recent studies have been conducted pro-
spectively and with sound methodology, relying on serum
hormone analysis to define the menstrual phase in addi-
tion to the LMP and have added significantly to the avail-
able data regarding the appropriate timing of breast
surgery.
There is still discordance between studies and well-con-
ducted prospective studies have provided evidence, both
for and against, rescheduling surgery to the luteal phase.
Meta-analysis [28] has demonstrated that luteal phase sur-
gery leads to improved survival and this policy has been
already adopted in some centres especially in node posi-
tive, and hormone receptor positive tumours. However
this meta-analysis should be interpreted with extreme
caution since it has significant inherent limitations
including the presence of significant heterogeneity
between studies, publication bias, the lack of defining cri-
teria for study inclusion and the lack of adjustments for
confounders and covariates.
Rescheduling surgery to coincide with the luteal phase
would appear to be a simple intervention that can be con-
sidered in order to improve outcome, however there are
further considerations. If scheduling surgery is dependant
on the hormonal status of the patient then the available
window for surgery becomes more limited, which will
place increased logistical demands on the unit and sur-
geons performing breast cancer surgery, it is even possible
that surgery may have to be delayed while waiting for the
appropriate phase.
While studies vary in their conclusions, it may be prudent
to defer the large scale rescheduling of breast cancer sur-
gery until a sound biological hypothesis is defined, and
corroborated by ongoing randomised controlled trials
that use biochemical testing to accurately define the cycle
phase. Furthermore, trials examining the potential role of
neo-adjuvant endocrine therapy to counteract unopposed
oestrogen during the follicular phase are required.
In addition to the cyclical variation in cell cohesiveness,
growth receptors and angiogenesis in tumours, there are a
number of hypotheses that may account for the potential
difference in survival. This underscores the need for fur-
ther studies aiming to define which specific mechanisms
may be responsible and such research will enhance our
understanding of mammary carcinogenesis.
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